LDLR and rheumatoid arthritis: Small-molecule Jak inhibitors have been shown to adversely impact serum lipid profiles; however, pro-atherogenic lipid changes and decreased hepatic LDL receptor expression were also demonstrated with tocilizumab in RA [34].